Experimental GLP-1 oral pill aleniglipron shows up to 12% weight loss in 36 weeks

A new oral glucagon‑like peptide‑1 (GLP‑1) medication, aleniglipron, has shown promising weight‑loss results in a recent clinical study. Participants who were overweight or obese reported an average reduction of 12.1 % of their body weight after 36 weeks of daily dosing, a figure that rivals the efficacy of currently approved injectable GLP‑1 therapies.

Unlike the injectable drugs Wegovy and Ozempic, aleniglipron is a small‑molecule pill that can be taken once a day with or without food. This oral format may simplify patient adherence and reduce the need for injection training. Additionally, the small‑molecule chemistry could allow for easier manufacturing and larger‑scale production, potentially lowering costs and increasing accessibility.

If the results are confirmed in larger trials, aleniglipron could become a valuable addition to the obesity‑treatment armamentarium, offering patients a convenient and effective oral alternative to existing injectable options.